A Study of Dalcetrapib in Patients Hospitalized for an Acute Coronary Syndrome - dal-OUTCOMES

Description:

Despite multiple attempts, no pharmacological agent thus far has been successful in increasing high-density lipoprotein (HDL) while reducing coronary events. Dalcetrapib is a cholesteryl-ester-transfer protein (CETP) inhibitor that has not shown off-target effects such as blood pressure elevation (noted with torcetrapib, another CETP inhibitor in the ILLUSTRATE trial) in early trials. The current trial was a phase III trial designed to assess the efficacy and safety of dalcetrapib on clin...